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Abbreviations 
AJCC/UICC/CAP American Joint Commission on Cancer/Union of 
International Cancer Control/College of American 
Pathologists 
APB ALT associated PML-NB 
ALT Alternative lengthening of telomeres 
ASVS Arterial stimulation venous sampling 
ATRX Alpha thalassemia/mental retardation syndrome X-linked 
CGH Comparative genomic hybridisation 
CIN Chromosome instability 
CNA Copy number alterations 
CT Computed tomography 
CUP Cancer of unknown primary 
DAPI 4’,6-diamidino-2-phenylindole dihydrochloride 
DAXX Death domain-associated protein 6 
DDR DNA damage response 
EC Enterochromaffin cell 
ENETS European Neuroendocrine Tumor Society 
EUS Endoscopic ultrasonography 
FDA Food and Drug Administration 
FGF Fibroblast growth factor 
FISH Fluorescence in situ hybridisation 
GI Gastrointestinal 
HE Haematoxylin & eosin 
HPF High-power field 
IHC Immunohistochemistry 
IRS Immunoreactive Remmele Score  
MANEC Mixed adenoneuroendocrine carcinoma 
MEN1 Multiple endocrine neoplasia, type 1 
MRI Magnetic resonance imaging 
mTOR Mammalian target of rapamycin 
n.a. Not assessable 
NE Neuroendocrine 
NEC Neuroendocrine carcinoma 
NET Neuroendocrine tumour 
NF1 Neurofibromatosis type 1 
NSE Neuron-specific enolase 
PANEC Pancreatic neuroendocrine carcinoma 
PANET Pancreatic neuroendocrine tumour 
PAS Periodic acid-Schiff staining 
PDGF Platelet-derived growth factor 
PET Positron emission tomography 
PML-NB Promyeloic leukaemia nuclear bodies 
PP Pancreatic polypeptide 
SiNET Neuroendocrine tumour of the small intestine 
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SNV Single nucleotide variant 
SRS Somatostatin receptor scintigraphy 
SWI/SNF SwItch/Sucrose NonFermenTable 
TMA Tissue microarray 
TMM Telomere maintenance mechanism 
TNF Tumour necrosis factor 
TNM Tumour (T), lymph node metastasis (N), distant metastasis 
(M) – classification system of malignant tumours 
TSC Tuberous sclerosis complex 
US Ultrasonography 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
VHL Von Hippel-Lindau 
VIP Vasoactive intestinal polypeptide 
WHO World Health Organization 
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1. Introduction 
 
1.1 Neuroendocrine tumour (NET) - neuroendocrine carcinoma 
(NEC)  
 
Neuroendocrine tumours (NETs) arise from neuroendocrine cells. These cells have 
neuroendocrine differentiation characterised by positivity for immunohistochemical 
markers such as synaptophysin and chromogranin and by secreting proteins such as 
normal endocrine cells [2]. Neuroendocrine cells (NE cells) are located in the 
gastrointestinal tract (GI tract), the lung, the urogenital tract, the cardiovascular system, 
the thyroid gland (C cells), the parathyroid gland, the adrenal medullary, the skin 
(Merkel cells), paraganglia, the hypothalamus, the pituitary gland and the pineal gland. 
In general, NETs are rare neoplasms with an incidence of 2-4 per 100,000 population 
[3], which is increasing at a rate of 3-10% per year, depending on the subtype [4]. One 
reason for this increase could be improved diagnostic methods. The distribution 
between the sexes is balanced [1]. The mean age of the first diagnosis is 56 years; the 
range is between 14 and 93 years [1]. NETs represent 0.5% of all malignant tumours 
[3]. Most NETs are found in the pancreas (34.2%) and the small intestine (25.8%) [1]. 
Tumours vary considerably in size, growth rate and biological behaviour. NETs can 
cause clinical symptoms due to the secretion of functional hormones, such as 
hypoglycaemia in patients with insulinoma [5]. Another example is the carcinoid 
syndrome with flush, diarrhoea and cardiac symptoms in patients with a serotonin-
producing tumour arising from enterochromaffin (EC) cells of the gastrointestinal tract 
[6]. Functional NETs are called functional because of their clinical presentation, not 
because of positive immunohistochemical staining. About 60% of NETs are non-
functional [1, 7] and are diagnosed when local symptoms of the primary tumour or its 
metastasis occur, or they are found accidentally. Lymph node metastases are often 
detected; at time of diagnosis, 50% of patients already have distant metastases, usually 
located in the liver [8, 9]. The time of diagnosis, the initial TNM classification and the 
grade of proliferation are relevant for the prognosis [10-12]. The probability of a five-
year survival time of a NET with distant metastasis is about 50-75% [13, 14]. Over the 
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last fifty years, the classification of NETs varied considerably until the WHO 
classification (Table 1) and the TNM classification of ENETS (see Chapters 
2.1 and 3.1) became standard in 2010. Well-differentiated neuroendocrine tumours 
are classified as neuroendocrine tumours (NETs) and not as carcinomas (NECs), even if 
they exhibit angioinvasion or metastasis. Neuroendocrine carcinomas (NECs) are 
diagnosed when they are poorly differentiated and the mitosis rate or the Ki-67 index is 
higher than 20%. Other features of NEC can be the presence of necrosis; recently, the 
importance of immunohistochemical staining with CK19 and c-kit has been under 
investigation. [15].  
 
 
 
The pathogenesis of NETs is not yet fully understood, but there are a few syndromes 
known that are associated with NETs: Von Hippel-Lindau (VHL), tuberous sclerosis 
complex (TSC1), neurofibromatosis type 1 (NF1) and multiple endocrine neoplasia type 
1 (MEN1). In these cases, the VHL or MEN1 gene is mutated or there are mutations in 
the neurofibromatosis gene locus [15].  
Figure 1 Distribution of localisation of primary NETs, modified [1]. CUP = cancer of 
unknown primary.  
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WHO 
classification 
2010 
 
 
 
 
 
Neuroendocrine 
tumour 
Neuroendocrine 
tumour 
Neuroendocrine 
carcinoma 
(NEC) 
 
Large cell 
Small cell 
Grade 
 
G1 G2 G3 
Ki-67(%) 
 
<2% 2-20% >20% 
Histological 
differentiation 
 
well well poor 
Mitosis 
 
<2/10 HPF 2-20/10 HPF >20/10 HPF 
Table 1: WHO classification 2010 of neuroendocrine neoplasms. WHO =  World Health 
Organization, HPF = high-power field [16] 
1.2 Insulinomas 
 
1.2.1 Pancreatic neuroendocrine tumours and insulinomas - Definition  
 
Pancreatic neuroendocrine tumours (PANETs) can be classified in several ways: by 
grade (see Table 1), by size and by functional status. The classification of PANETs by 
functional status is described below (Tables 2 and 3). In addition, there are two different 
staging classifications of PANETs: AJCC/UICC/CAP (American Joint Commission on 
Cancer/Union of International Cancer Control/College of American Pathologists) and 
ENETS (European Neuroendocrine Tumor Society). The ENETS classification was 
more significant in correlation with the risk of death [17, 18]. It is state of the art to 
apply both (Table 4).  
Insulinomas are well-differentiated neuroendocrine tumours arising in the β cells of the 
Langerhans islets of the pancreas that produce insulin. About 10% of all insulinomas 
exhibit malignant behaviour [19-23]. The median survival of patients with metastases in 
the liver, bone or lymph node is < 2 years [24]. 
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Table 2: Classification of pancreatic neuroendocrine tumours (PANETs) . [25] 
Diagnosis Cell type Syndrome Clinical findings Percentage of 
functional PANETs 
Glucagonoma α cell  Glucagonoma 
syndrome 
Rash, stomatitis, 
diabetes, weight 
loss 
8-13% [26] 
Somatostatino
ma 
δ cell  Somatostatinoma 
syndrome 
Diabetes 
hypochlorhydria, 
cholelithiasis  
2% [27] 
Insulinoma β cell  Insulinoma 
syndrome 
 
Hypoglycaemia  42% [5] 
Gastrinoma G cell  Zollinger-
Ellison 
syndrome 
Peptic ulcers,  
diarrhoea 
 
Second common 
functional PANET 
VIPoma Unknown Verner-Morrison 
syndrome 
Watery diarrhoea, 
hypokalaemia, 
achlorhydria  
10% [28] 
PP cell PANET PP cell  None None (ev. 
elevated levels of 
PP) 
 
Table 3: Types of functional PANETs. Insulinomas represent the most common 
functional PANETs [5].   
Classification of pancreatic neuroendocrine tumours (PANETs) 
 
Endocrine micro adenoma  
 
 
Well-differentiated 
PANETs 
Functional 
 
 
 
 
 
 
 
 
Non-functional PANET 
Insulinoma 
Glucagonoma 
Somatostatinoma 
Gastrinoma 
VIPoma 
PP cell PANET 
Ectopic and mixed 
hormone-producing 
neoplasia 
 
Poorly differentiated 
PANETs 
  
 Small cell carcinoma 
 Large cell carcinoma 
Mixed endocrine 
carcinomas 
 
Mixed ductal-endocrine carcinoma 
 Mixed acinar-endocrine carcinoma 
 Mixed acinar endocrine ductal carcinoma 
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T AJCC/UICC/CAP TNM ENETS TNM 
 
T1 Confined to pancreas, <2 cm Confined to pancreas, <2 cm 
 
T2 Confined to pancreas, >2 cm Confined to pancreas, 2-4 cm 
 
T3 Peripancreatic spread, without 
infiltration of the coeliac trunk or the 
A. mesenteria superior 
 
Confined to pancreas, > 4 cm or 
invasion of the duodenum or bile duct 
 
T4 Peripancreatic spread, with infiltration 
of the coeliac trunk or the A. 
mesenteria superior 
 
Invasion of adjacent organs or major 
vessels 
Table 4: Staging classifications of pancreatic neuroendocrine tumours (PANETs) 
Historically speaking, the first adenoma of pancreatic islets was reported by Nicholls in 
1902; the first insulinoma was described in 1927 in Mayo Clinic. The first enucleating 
was performed in 1931 in St. Louis, Missouri [29]. In 1935, Whipple and Franz 
described the clinical symptoms of this tumour. [30] 
1.2.2 Epidemiology 
 
Insulinomas are most common among functional PANETs, accounting for 42% [5]. The 
incidence of insulinomas is four per million cases a year, and is increasing [30, 31]. One 
reason for this could be that better diagnostic methods exist, which are able to find even 
the smallest tumour. The distribution between sexes is balanced at a ratio of 1:1.4 (M: 
F). Other studies yield a slightly higher occurrence in men [23]. Most insulinomas occur 
in patients at the age of 40-60 years (mean 46 years), but an occurrence between 20-40 
is also common [23, 32].  
1.2.3 Aetiology 
 
A recent review of 6,222 cases reported that 94% of all insulinomas are sporadic [23]. 
Familial insulinomas are mainly due to autosomal dominant mutations in the MEN1 
(multiple endocrine neoplasia type 1) gene. This gene operates as a tumour suppressor 
gene; mutations lead to the inactivation of its function, and tumours in the pancreas, 
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parathyroid gland (more than 90%), duodenum (50-85%) and pituitary gland can occur. 
It is rare to find additional tumours in other regions such as lung, thymus, andrenal 
gland and thyroid in these patients [33-36]. However, insulinomas are often multiple in 
patients with MEN1 syndrome. Another disease involving multiple insulinomas is 
insulinomatosis, with the occurrence of synchronous and metachronous insulinomas 
[37]. Neurofibromatosis type 1 (NF1), the von Hippel-Lindau disease (VHL) and 
tuberous sclerosis complex (TSC) known as familial diseases with NETs are uncommon 
for insulinomas [38-43]. 
Little has been reported about the risk factors for developing insulinomas. An Italian 
study of 17 patients with insulinomas reported that a family history of cancer and 
alcohol abuse are risk factors [44]. A Chinese study [45] included 196 patients with 
insulinomas and compared them with a control group (benign or malignant tumours, 
autoimmune or genetic diseases were excluded) of 233 patients who underwent surgery. 
12% of the study group had MEN-1-related insulinomas. This study also showed that in 
sporadic insulinomas a family history of cancers, especially of PANETs, is a risk factor. 
They found no correlation between alcohol consumption and the occurrence of 
insulinomas, consistent with the results of a number of studies from the USA [46, 47]. 
A high body mass index (BMI) and cigarette smoking are not associated with 
insulinomas. Recent studies explore molecular pathological changes, mentioned in 
Chapter 1.2.8. 
1.2.4 Clinical presentation 
 
Patients with insulinomas suffer early from hypoglycaemia and the resulting 
catecholamine response, rather than from local complications, because the tumour is 
usually very small [5].There is no correlation between the size of the tumour and the 
severity of symptoms [5, 48]. Hypoglycaemia causes symptoms such as diplopia, 
blurred vision, confusion and fatigue. It can also lead to unconsciousness and seizures. 
Hypoglycaemia can also mimic cardiovascular diseases or movement disorders such as 
hemiplegia or hemiballismus [49, 50]. The effects of catecholamine response are 
hunger, weakness, perspiration, palpitations, sweating, anxiety and nausea.  
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In conclusion, insulinoma causes the so-called “Whipple trias”, including 
hypoglycaemia symptoms, low blood glucose levels (< 3.0 mmol/l or < 55 mg/dl) and 
improvement by administering glucose. 
In rare cases, the tumour can grow to 10 cm in diameter [22] and cause local problems 
such as abdominal pain, weight loss and, if the tumour constricts the choledochus duct, 
jaundice. 
1.2.5 Diagnosis 
 
As mentioned above, post-prandial low blood glucose levels are a reason to suspect an 
insulinoma. Plasma insulin and prosinsulin are elevated, particularly after a period of 
fasting [5]. The gold standard is to measure the plasma glucose, insulin, C-peptide and 
proinsulin over a 72-hour fasting period. 99% of all insulinomas can be detected using 
this diagnostic method [51]. In order to localise the tumour, non-invasive diagnostic 
methods are used, including transabdominal ultrasonography (US), computed 
tomography (CT) and magnetic resonance imaging (MRI). The sensitivity of 
transabdominal US is poor, at 9%-64% [30]. The sensitivity of CT and MRI is 33%-
64% and 40%-90% [52, 53]. When the tumour grows extra-pancreatic, the sensitivity 
and specificity of MRI is superior to that of CT [54]. 
Figure 2: CT imaging of an insulinoma located in the pancreas [55]. Since insulinomas 
are hyper vascular tumours, a greater enhancement in the arterial and capillary phase in 
contrast to the normal pancreas parenchyma is visuali sed [54] 
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Figure 3: MRI of an insulinoma [55]. Insulinomas are detected as low signal intensity on 
T1-weighted images (A) and high signal intensity on T2 -weighted images (B) [56]. 
CT is currently accepted as first line investigation. It visualises the exact localisation of 
the tumour and its relationship to neighbouring structures. It also shows the presence of 
metastasis [53]. Insulinomas are known as hyper vascular tumours, so in CT the tumour 
shows a greater enhancement in the arterial and capillary phase than the surrounding 
tissue [54]. In MRI, insulinomas are detected as low signal intensity on T1-weighted 
images and high signal intensity on T2-weighted images [56]. A highly sensitive (94%-
100%) [57, 58] invasive diagnostic method is angiography combined with arterial 
stimulation venous sampling (ASVS) to exactly localise the tumour prior to surgery. 
Invasive diagnostic methods such as endoscopic ultrasonography (EUS) and ASVS are 
useful for precisely localising the tumour prior to surgery. In EUS, insulinomas are 
visualised as hypo-echoic rounded mass with distinct margins. Some insulinomas may 
be missed in this method because they are isoechoic or because of other artificial 
reasons that occur in a special collective of patients [59]. Detection rates of 86.6%-
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92.3% are reported [52, 60]. EUS-guided fine-needle aspiration (FNA) is becoming 
increasingly popular in the preoperative diagnosis of insulinomas. Another diagnostic 
method, specific for NETs, is the 
68
Ga-DOTATATE PET, which uses a radioactively 
labelled somatostatin analoga. The 
68
Ga-DOTATATE PET was reported to detect NETs 
as small as 6 mm [61]. According to recent ENETS guidelines, it is recommended for 
localising the primary of metastatic NETs [62]. In some cases, surgical exploration, 
intraoperative ultrasound and manual palpation of the pancreas by an experienced 
surgeon are required [63-65] . 
1.2.6 Gross findings 
 
Insulinomas are small red to brown, soft, well-circumscribed homogenous tumours 
without a capsule. They can occur in any part of the pancreas. They are found extra-
pancreatic extremely rarely, usually in the duodenal wall [66]. They normally measure 
between 0.5-1.0 cm; 25% are larger than 2 cm. [48]. Cases involving a size of 10 cm or 
more have also been described [22]. Bigger tumours are reported to be more likely to be 
malignant. The majority (about 90%) are solitary [23]; multiple insulinomas are 
documented in MEN1 syndrome and insulinomatosis. They are multiple extremely 
rarely, in sporadic cases.  
 
Figure 4: Neuroendocrine tumour of the pancreas shown as a yellowish well -
circumscribed nodule with a diameter of 4  mm.  
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1.2.7 Histological findings 
 
Insulinomas grow in a solid/nested, trabecular, micro glandular or acinar pattern. They 
do not have a capsule, although larger ones may have a pseudo capsule. Stromal 
hyalinisation or amyloid deposits may be present, and calcifications or psammoma 
bodies can also be seen. The monomorphous cells have a polygonal shape. A typical 
nuclear feature is the “salt and pepper”-like chromatin pattern. The criterion for 
malignant behaviour is the detection of lymph node or distant metastases. 
Morphologically, there is no difference between benign and malignant insulinomas. 
 
Immunohistochemistry of PANETs: In general, more than 95% of all PANETs are at 
least positive for one endocrine marker, such as chromogranin A and synaptophysin, or 
CD56 [67].  
Chromogranin A is part of the membrane of large dense-core secretory vesicles; its 
function is to complexate peptide hormones. Synaptophysin is known as part of small 
synaptic vesicles, which are found in all NE cells. CD 56 is a synonym for the neural 
cell adhesion molecule (NCAM), and is expressed on the surface of NE cells and other 
cells such as neurons, glia, skeletal muscle and natural killer cells. CD 56 plays inter 
alia an important role in cell adhesion. 
MIB1/Ki-67 staining is a fundamental method of demonstrating the rate of proliferation, 
which is important when grading the tumour (see Table 1, Chapter 1.1). Some peptides 
can be positive in PANETs, such as glucagon, gastrin, insulin, pancreatic polypeptide 
and somatostatin. There is often a correlation between the functional presentation of the 
tumour and immunohistochemistry results. 
Immunohistochemistry of insulinomas:  Insulinomas should stain positive for insulin 
and proinsulin. The reason why insulinomas may not stain positive for insulin could be 
that they secrete the peptide but there is no accumulation, so it cannot be detected by 
immunohistochemistry staining. Another reason could be that the peptide is changed 
and is negative for staining, but still has its functional activity. About 50% of 
insulinomas are positive for other peptides such as glucagon, gastrin, pancreatic 
polypeptide and somatostatin [32].  
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Figure 5: HE, 200x, insulinoma; monomorphic cells with eosinophilic cytoplasm, 
disposed in a trabecular and pseudo glandular  pattern.  
. 
Figure 6: HE, 630x, insulinoma; typical salt  and pepper chromatin pattern.
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Figure 7: Chromogranin staining, 200x. Chromogranin staining shows a focally strong 
positivity.  
 
Figure 8: Ki-67, 200x. Ki-67/MIB1 staining shows a positivity of 3%. 
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Figure 9: Synaptophysin, 200x. The tumour cells are strongly positive for synaptophysin.  
 
Figure 10: Insulin, 200x. Insulin staining is positive.  
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1.2.8 Molecular pathology 
 
MEN1/VHL: Familial PANETs such as MEN1 syndrome and VHL syndrome are 
associated with mutations in the MEN1 and in the VHL gene [68, 69], as mentioned 
above (see Chapter 1.2.3). In about 40% of sporadic insulinomas [70], mutations in the 
MEN1 gene or loss of heterozygosity in the MEN1 gene are reported, which are 
associated with a better prognosis [71-74]. Pancreatic neuroendocrine carcinomas 
(PANECs) are commonly not associated with alterations in the MEN1 gene. Deletions 
in the VHL gene are also documented in sporadic cases [42]. 
DAXX/ATRX:  Recent studies (see Table 7, Chapter 1.7) explore mutations in the DAXX 
and ATRX gene. A loss of expression in immunohistochemical staining is reported in 
45% of cases of DAXX and ATRX mutations [75].  
mTOR-Pathway: Mutations in PI3K, a member of this pathway, are reported in 1.4% of 
cases [70, 76, 77]. Mutations in the PTEN gene are more common in 10-29% of cases 
[70, 76, 77]. The TSC2 (tuberous sclerosis gene, encoding for the protein tuberin) gene, 
another member of this pathway, was mutated in 8.8% of PANETs [70, 76, 77]. No 
mutations of mTOR in PANETs are found [77, 78]. In conclusion, 16% of all cases 
exhibit mutations in this pathway [76, 77], which is already a target for therapy in 
advanced neuroendocrine tumours (see Chapter 1.2.9) [79].  
Numerous chromosomal aberrations were detected in a study cohort of 37 primary 
PANETs and 11 metastasis with copy number gains in Chromosome 06p22.2-p22.1 
(27.1%), 17p13.1 (20.8%) 7p21.3-p21.2 (18.8%), and 9q34.11 (18.8%). Genomic loss 
was observed at 8q24.3 (6.3%). Copy number alterations (CNAs) were heterogeneous 
between the metastasis and primary tumour, and slightly increased in metastasis [80]. 
Mutations detected in the ductal pancreatic adenocarcinoma such as KRAS, TGF-β, 
CDKN2A or TP53 are not usually seen in PANETs, and vice versa [81-84] 
For insulinomas in particular, little is reported about their molecular pathology.  
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1.2.9 Therapy and prognosis 
 
In most cases, a resection of the tumour cures the patient. Enucleation of the tumour is 
usually carried out (56%). About 32% of patients undergo a distal pancreatectomy; in 
3% a Whipple procedure is performed. Fistula represent a worrisome surgical 
complication. Recurrence of the tumour is reported in 7% of cases [23]. About 10% of 
all insulinomas exhibit malignant behaviour with lymph node metastases, local 
(peritoneum) and distant metastases. Most of these tumours measure more than 2 cm 
[85]. In those cases, systemic therapy is indicated. The treatment is identical to that for 
other PANETs, besides treatment for hormone-related symptoms. In addition to dietary 
recommendations, octreotide and diazoxide are administered to control hypoglycaemia 
symptoms. Octreotide is administered after a positive octreotide scan for expression of 
somatostatin receptor [86, 87]. Diazoxide is a potassium channel opener that inhibits the 
secretion of insulin [88]. The side effects of diazoxide are oedema and hirsutism; 
recurrence of the symptoms is also common [89]. Local palliative treatment for patients 
with liver metastases who are not candidates for surgery includes selective bland 
embolisation, chemoembolisation and radio embolisation [90, 91]. For metastatic 
insulinomas, systemic cytotoxic therapy and systemic targeted therapy are available. 
Systemic cytotoxic treatments are streptozocin, 5-FU, platinum and temozolomide. 
Tumour respond rates for streptozocin plus doxofubicin or 5-FU range from 16-69% 
[92-94]. Targeted therapies are based on the following pathways: PI3K/Akt/mTOR 
pathway and angiogenesis in insulinomas. Although mutations of MEN1 are most 
common, there is no targeted therapy as yet. There is also no special therapy for 
DAXX/ATRX-mutated PANETs. As mentioned above, these mutations are correlated 
with the ALT pathway. The development of efficient ALT inhibitors could establish 
new targeted therapies such as targeted therapy for telomerase inhibitors, which already 
exist. 
Targeted therapies 
Pi3k/Akt/mTOR pathway: The function of mTOR (mammalian target of rapamycin) 
is the regulation of cell metabolism, proliferation, survival and coordination of protein 
translation [95]. 410 patients with advanced PANETs were included in a placebo-
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controlled phase III study (RADIANT-3). Compared to the placebo group, patients who 
were treated with the mTOR inhibitor everolimus showed a significantly prolonged 
survival time (11 vs. 4.6 months) [79]. Combining everolimus with other drugs, vertical 
inhibition or targeting another pathway, are under investigation.  
Angiogenesis:  Like other PANETs, insulinomas are well-vascularised neoplasms. 
There are contradictory results about the correlation between expression of PDGF 
(platelet-derived growth factor), FGF (fibroblast growth factor) or VEGF (vascular 
endothelial growth factor) and the biological behaviour of insulinomas. However, it is a 
fact that these proteins are expressed in insulinomas and/or the surrounding endothelia 
[77]. Consequently, the inhibition of neoangiogenesis is a treatment option in 
insulinomas. The application of sunitinib, a tyrosin kinase inhibitor which is approved 
in treatment of insulinomas, resulted in a longer survival time of 10.2 vs. 5.4 months in 
a placebo-controlled phase II study [96]. Sorafenib is another agent that inhibits 
VEGFR2, PDGFR, FGFR1 and RAF [97, 98]. Another drug, which demonstrates a 
partial response of 18.9%, is an inhibitor of VEGFR1, PDGFR and c-kit, called 
pazopanib. The progression-free survival was 9.5 months [99]. An antibody against 
VEGF is bevacizumab, which is approved in the treatment of several tumours such as 
colorectal cancer, breast cancer, lung cancer  and tumours of the urogenital tract. This 
drug is combined with others such as temozolomide or octreotide in phase II studies 
with a partial response (86% and 18%, respectively). The progression-free survival was 
14.3 months and 15 months [100, 101]. However, bevacizumab is not approved in the 
treatment of insulinomas. 
Prognosis 
Patients with benign insulinomas (90%) have an excellent prognosis and can be cured 
by enucleation of the tumour. The median survival of patients with metastatic 
insulinomas is three years for G1 graded tumours, and 24 months for G2 graded 
tumours [102]. Among immunohistochemical markers, CK19 [103] was significantly 
predictive, while others under investigation like such as CD99, COX2 and p27 [104] 
failed to be labelled as prognostic markers. Proteins ALDH1A1, VDAC1 and TPD52 
recently proved to be biological markers [105]. 
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1.3 Neuroendocrine tumours of the small intestine 
1.3.1 Definition 
 
Neuroendocrine tumours of the small intestine (siNETs) are well-differentiated tumours 
of neuroendocrine origin. They are the second most common neuroendocrine neoplasms 
(26%) [1]. They are graded as G1, with a proliferation index of <2%; G2 has a 
proliferation index between 2% and 20%. According to WHO 2010, neuroendocrine 
neoplasms with a poor differentiation and a proliferation rate higher than 20% are called 
neuroendocrine carcinomas. These can be differentiated into small and large cell NEC 
(see Chapter 1.1., Table 1). NECs are virtually never seen in the small intestine. 
Other subtypes of neuroendocrine neoplasms of the small intestine are: mixed 
adenoneuroendocrine carcinoma (MANEC), enterochromaffin cell (EC) serotonin-
producing NET, L cell glucagon-like peptide-producing, PP/PYY-producing NET, and 
the following, which usually appear in the duodenum: somatostatin-producing  NET, 
gangliocytic paraganglioma and gastrinoma. 
Classification of neuroendocrine neoplasms of the small intestine  
 
Neuroendocrine tumour (NET) NET G1 
NET G2 
 
 
Neuroendocrine carcinoma (NEC) Large cell NEC 
Small cell NEC 
 
Mixed adenoneuroendocrine carcinoma (MANEC) 
 
  
EC cell serotonin-producing NET  
  
L cell, glucagon-like peptide-producing and PP/PYY-
producing NETs 
 
 
Somatostatin-producing NET 
 
Gangliocytic paraganglioma 
 
Gastrinoma 
 
 
Table 5: WHO classification of neuroendocrine neoplasms of the small intestine (2010).  
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T AJCC/UICC/CAP 
TNM 
 
 
 
T1 Infiltration of the lamina propria, 
<1 cm 
 
 
T2 Infiltration of the muscularis 
propria, >1 cm 
 
 
T3 Infiltration of the subserosa* 
 
 
T4 Infiltration of the serosa or other 
structures 
 
Table 6: Staging classifications of neuroendocrine tumours of the small intestine.  * 
Tumours of the duodenum: infiltration of the retrope ritoneal space or the pancreas.  
 
1.3.2  Epidemiology 
 
The incidence of NETs in the jejunum and ileum is 0.3-1.1 per 100,000 population 
[106, 107]. At first diagnosis, patients are between 50 and 70 years old. The distribution 
between sexes is balanced [7, 107].  
1.3.3  Aetiology 
 
NETs of the small intestine are sporadic neoplasms, although a few familial occurrences 
are reported. The genetics in these cases remain unclear [107]. Common hereditary 
diseases such as MEN1, VHL and NF1 are not documented in siNETs. There are no 
known risk factors, but an increased risk with a family history of NETs is suggested 
[14]. An occurrence with other tumours, especially colorectal carcinomas, is 
documented [108, 109]. Genetic alterations in siNETs are discussed in Chapter 1.3.8. 
1.3.4  Clinical presentation 
 
SiNETs are diagnosed accidently, or because of clinical symptoms of hormone-
producing tumours, or because the primary or the distant metastasis causes local 
UICC 
Stage 
T N M 
 
 
 
I T1 N0 M0 
 
IIA T2 N0 M0 
IIB T3 N0 M0 
IIIA T4 N0 M0 
IIIB Any T N1 M0 
IV Any T Any N M1 
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symptoms. Local clinical presentations such as abdominal pain, subileus and ischemia 
may occur. In these cases, local metastases are already present, which induce 
desmoplasia of the stroma and lead to motility disorders of the intestine [110]. Many 
siNETs are functional neoplasms that produce hormones such as serotonin, bradykinin, 
tachykinin or substance P[38]. The so-called carcinoid syndrome, first described by 
Thorson and Hedinger, arises when there are already metastases in the liver, because 
otherwise the substances mentioned above would be degraded in the liver. The 
symptoms are flush (90%), diarrhoea (80%), constriction of the bronchus (10%) and 
abdominal pain [111]. 15-20% of patients with liver metastasis suffer from the carcinoid 
syndrome [107]. Carcinoid heart disease occurs in patients with elevated circulating 
blood serotonin levels, and leads to fibrotic changes in heart valves and further to 
cardiac dysfunction [112-114]. 
1.3.5   Diagnosis 
 
The hormones mentioned above and inactive proteins produced by NETs are considered 
as tumour markers. Although chromogranin A is a sensitive marker, it is less specific 
and therefore not recommended as a screening test [115]. However, because it is not 
metabolised in the liver the level of Chromogranin correlates with the tumour level, and 
is therefore a good marker of surveillance [107, 116]. 5-HIAA, a metabolic substance 
derived from serotonin, is measured in a 24-hour urinary excretion in patients with 
suspected carcinoid syndrome [117]. Measuring serotonin in blood samples was not 
specific, but a recent study yielded a 89% sensitivity and 97% specificity for plasma 
serotonin in those patients [118]. Other substances such as neuron-specific enolase 
(NSE), substance P, neurokinin A and pancreastatin failed as tumour markers [112, 119, 
120]. CT, MRI scans and somatostatin receptor scintigraphy (SRS, OctreoScan) are the 
diagnostic methods used to localise the tumour. In the CT scan, the tumour exhibits an 
enhancement during the arterial phases, because it is a well-vascularised tumour [121]. 
Metastases often produce desmoplastic fibrosis, which can be detected by CT scans or, 
since it is reported to be more sensitive, by MRI [122]. SRS is not only important as a 
diagnostic method, but is also relevant for peptide receptor radiotherapy to predict 
response to treatment [123, 124]. 
68
Ga-DOTATATE PET yielded a 81% sensitivity and 
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a 90% specificity for localising the primary of metastatic NETs and is recommended by 
ENETS [61] 
1.3.6  Gross findings 
 
In 70% of cases, NETs of the small intestine are located in the ileum, usually in the 
distal part. In 2% of cases, the primary is located in a Meckel diverticula [42, 125]. The 
diameter is <1 cm in 13% of cases, and <2 cm in 47% [125]. 2% of neoplasms, which 
are smaller than 1 cm, exhibit metastatic lymph nodes. When the diameter exceeds 2 
cm, the likelihood of finding metastatic lymph nodes is 100% [126]. Metastases can 
also be located in the liver, peritoneum and bone marrow. 20-40% of siNETs are 
multiple [127]. Grossly, they are well-circumscribed yellowish nodules without a 
capsule.  
Figure 11: Submucosal NET, shown as a well -circumscribed yellowish nodule, which is 
not infiltrating the tunica muscularis. M = mucosa, musc = Tunica muscularis.
M 
Musc. 
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1.3.7  Histological findings 
 
Histologically, the tumour exhibits an insular, solid, and glandular-cribriform pattern. If 
present, the muscle invasive part has a retiform pattern. The cells are round and 
monomorphic. The chromatin shows the typically salt and pepper aspect; mitotic 
activity is rarely seen. The cells are negative for PAS (periodic acid-Schiff staining). 
Necrosis and apoptosis are not common. Angioinvasion, lymphangiosis and invasion of 
nerves can be detected. Bordering mesenteric vessels can be obliterated due to 
obliterating intima fibrosis, which leads to ischemia [107]. Immunohistochemically, the 
tumour stains positive for synaptophysin and chromogranin A. CD56 is also a marker 
for NETs, but is less specific [107]. MIB1/ Ki-67 is an obligatory proliferation marker 
in pathological diagnosis. The Ki-67 index provides information about grading and 
prognosis [107]. Immunohistochemical positivity of the primary for somatostatin 
receptors is important for surveillance control and finding distant metastases in 
somatostatin receptor scintigraphy (SRS), especially when no presurgical SRS was 
performed. In fact, there is an over 90% correlation between immunohistochemistry and 
SRS-based results [123, 124]. 
 
Figure 12: HE, 25x. Well-circumscribed lesion with a nested and cribriform pattern.  
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Figure 13: HE, 100x. The tumour exhibits a nested as well as cribriform pattern. The 
mucosa is not affected.  
 
 
Figure 14: The tumour is strongly positive for synaptophysin and chromogranin A.  
A: 200x synaptophysin, B: 200x chromogranin A  
.
A B 
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Figure 15: Ki-67, 200x. Since the proliferation index is lower than 2%, it is graded as G1 
NET. 
 
1.3.8  Molecular pathology 
 
SiNETs are described as genetically stable cancers by a study of 48 siNETs, revealing 
an average of 0.1 SNVs per 10^6 nucleotides. Mutations relevant for targeted therapies 
were found in the following genes: SRC, SMAD family genes, AURKA, EGFR, HSP90 
and PDGFR [128]. Further somatic mutations in the cyclin-dependent kinase inhibitor 
(CDKN1B) gene were found. This gene encodes for the protein p 27, which operates as 
a tumour suppressor [129]. In 69% of ileac neuroendocrine tumours, allelic loss of 
Chromosome 18 was found [130, 131]. Research conducted by our study group 
involves genes located on Chromosome 18 such as DCC, Smad2, Smad4/DPC and 
Maspin/SerpinB5. Immunohisochemically, there was no loss of expression of the 
protein products of these genes. Smad4 was expressed in 97% of the tumours (J. Brix, 
Master thesis). In addition, an exome sequencing of five siNETs was performed, and 
more than 590 single nucleotide variations (SNV) were found. Mutations in genes 
located on Chromosome 18 (CABYR, NFATC1, PIEZO2, PIK3C3, LAMA3) and other 
genes such as ERBB2, ERCC4 and MSH6 were re-sequenced by Sanger sequencing. 
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However, it transpired that none of these targets play a major role in the pathogenesis of 
siNETs (L. Stoß, Master thesis).  
 
1.3.9  Therapy and prognosis 
 
Depending on the localisation of the primary, a right hemi colectomy, a small bowel 
resection or, in some cases when the tumour is close to the ampulla of Vater, Whipple 
surgery is performed [132]. At an early stage, surgical resection is a curative therapy; in 
advanced disease, surgical resection of primary and/or distant metastases can be 
performed to reduce clinical symptoms and complications such as bleeding and ileus 
[133]. Somatostatin analogues such as octreotide and lanreotide are used to reduce 
carcinoid symptoms; in 24-57%, a stabilisation of tumour growth is reported [134]. As 
mentioned above, somatostatin receptors on tumour cells are useful for peptide receptor 
radiotherapy, which is why SRS is performed. Depending on the findings, radioactive 
marked somatostatin is administered. A 23% response among patients with carcinoid 
syndrome was revealed [135]. Trials with interferon α were performed, since interferons 
have an effect on the stimulation of T-cells, the inhibition of angiogenesis and the 
induction of cell cycle arrest. However, several studies give no definitive conclusion 
about the overall survival, and no optimal doses of treatment were established [136]. In 
contrast to PANETs, everolimus,  an mTOR inhibitor extensively studied in NETs, is 
not approved by the FDA for the treatment of siNETs. Everolimus resulted in a 
progression-free survival of 16.4 vs. 11.3 months compared to the placebo group; this 
result fell short of statistical significance [137]. Several studies have been performed 
with the inhibition of VEGF. Results suggest that the antibody VEGF bevacizumab in 
combination with other agents (mTOR inhibitors and interferons) is effective in 
advanced disease [138]. However bevacizumab is not approved in treatment of 
neuroendocrine tumours. For NECs, chemotherapeutical drugs such as etoposide and 
cisplatin are administered, which show a good response (70%) in the first 8-10 months 
[139]. 
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1.4 DAXX (death domain-associated protein 6) 
 
DAXX, death domain-associated protein 6, is also known as BING2 and DAP6. The 
DAXX gene is located on 6p21.3 and consists of eight exons. DAXX protein is found in 
the nucleus as well as in the cytoplasm. It plays an important role in apoptosis. Three 
isoforms generated by alternative splicing are known. 
 
DAXX plays an important role in the Fas/JNK pathway: When Fas-receptor 
(=APO1, CD95), a TNF (tumour necrosis factor) receptor, is stimulated, DAXX is 
activated. This induces the c-JUN-N-terminal kinase pathway by activating the JNK 
kinase kinase ASK1 (apoptosis signal-regulation kinase1). JNK then activates HIPK2 
(home domain interacting protein kinase2), which transfers DAXX from the nucleus 
into the cytoplasm and reactivates ASK1 [140]. Bcl2 is able to block DAXX and 
prohibit apoptosis. 
Another mechanism that activates the JNK pathway is when TGF-β (transforming 
growth factor) is stimulated, which activates HIPK2 and phosphorylates the DAXX 
protein.  
Stress stimuli such as glucose reduction, UV radiation and oxidative stress are also 
capable of inducing the JNK pathway by activating DAXX [141]. In immortal cells 
such as HeLa cells, both pathways the DAXX and the FADD-induced cell death 
pathways  have to be blocked to prevent Fas-induced apoptosis [142]. Overexpression 
of DAXX induces the activation of JNK and multiplies the Fas pathway to apoptosis. 
[142]. In addition, DAXX is able to supress transcription factors such as p53, p73 and 
NF-κB. 
DAXX in the nucleus: DAXX also acts as a component of promyelocytic leukaemia 
nuclear body (PML-NB) in the interphase. Histone H3.3 is targeted to PML-NBs in a 
DAXX-dependent fashion, instead of being localised at senescence-associated 
heterochromatin foci (SAHF). An overexpression of DAXX leads to an enhancement of 
the targeting of H3.3 [143]. 
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Figure 16: The role played by DAXX in apoptosis by interacting with JNK, after binding 
with FAS. Bcl2 is able to block DAXX.   
 
1.5 ATRX (alpha thalassemia/mental retardation syndrome X-linked) 
 
ATRX is a member of the SWI/SNF (SwItch/Sucrose NonFermentable) helicase family; 
its main function is to remodel the chromatin structure [144]. The gene is located on 
Chromosome Xq13.3. The ATRX protein consists of 2,492 amino acids; the following 
regions can be distinguished: DNA-binding domain, a large exon, a polyglutamic acid 
stretch, the seven conserved helicase motifs found in DNA-stimulated ATPase and 
DNA helicase and a glutamine-rich domain [145, 146]. A mutation in the ATRX gene on 
the locus Xq21.1 in men can cause the alpha thalassemia mental retardation X-linked 
syndrome. These patients have particular facial features with hypertelorism, a snub nose 
and an everted lower lip. They are mentally retarded, the genitals are often malformed, 
and the testes fail to descend. The ATRX protein is associated with EZH2, which plays 
a major role in neuronal development [144]. Further, VAV1-EZH2-ATRX is known as 
a complex, which plays an important role in haematopoiesis. [144]. 
Together, DAXX and ATRX deposit the histone H3.3 at telomeres. The consequence 
remains unclear [147-151]. There is evidence that decreased ATRX and H3.3 leads to a 
destabilisation of the telomeres and an up-regulation of telomere repeat sequences 
[149]. 
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1.6 Telomeres and alternative lengthening 
 
Telomeres are localised at the end of each chromosome and consist of repetitive 
sequences (TTAGGG in humans), which are repeated several thousand times. The 
telomere can fold itself back and build a loop [152]. Another form is a t-circle, which 
comes out of telomere loop junctions [153]. A shelterin complex binds to the telomere 
repeat sequences and regulates its function. It comprises the following proteins: POT1, 
TPP1, TIN2, TRF1, TRF2 and RAP1. The complex prevents the telomeric DNA from 
being detected as a DNA double-strand break (DSB) [154]. 
Figure 17: Fluorescence in situ hybridisation showing the chromosomes in the metaphase 
with red fluorescent telomeres [155].  
Telomeres are important for the stabilisation of DNA. Every time the cell enters the S-
Phase (synthesis) and DNA replication starts, telomeres get shorter because, at the end 
of the chromosome, there is no 3’ where the primase can bind. This shows how 
important telomeres are they protect the sequences lying before them, otherwise 
important information would get lost. This is called the end-of-replication problem 
[156]. Due to this end-of-replication problem, telomeres lose some kb (kilo base) with 
every replication. When telomeres are shorter than 4 kb, a point is reached and cell 
division is no longer possible. Then DNA damage response factors (DDR) induce either 
programmed self-destruction (apoptosis) or senescence [157]. This turning point is 
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called the Hayflick limit. In senescence, cells are still active but unable to replicate. 
Senescence is also induced by oncogenes such as H-RasV12 when DNA damage is 
recognised [158, 159]. At the Hayflick limit, if there is also a loss of tumour suppressor 
genes (such as p53) or if the cell is exposed to radiation or carcinogenic substances or 
viral oncogenes are activated, then the cell proliferates and the already short telomeres 
become too short and the cell enters the M2 phase (crisis) [160]. This means that the 
cell can either go into apoptosis or it activates telomerase, an enzyme that can lengthen 
the ends of chromosomes with repeat sequences independent of primase. Cells with 
activated telomerase are now immortal cells, and have the unlimited potential to 
replicate. Normal cells with already activated telomerase without any damage to the 
DNA are germ cells and stem cells. Telomerase is a reverse transcriptase enzyme, a 
conglomerate of protein and RNA, which is able to rebuild sequences at the end of 
telomeres [161]. The RNA component is complementary to the repeat sequence of the 
telomere [162]. 
 
Figure 18: How normal cells become tumour cells by activating either telomerase or the 
ALT pathway.
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ALT (alternative lengthening of telomeres) 
85% of all tumours activate telomerase [163]. Another possibility for a telomere 
maintenance mechanism (TMM) is the ALT pathway (alternative lengthening of 
telomeres). Tumours with a mesenchymal and neuroepithelial origin tend to the ALT 
pathway [164, 165]. It is commonly found in osteosarcoma, soft tissue sarcomas, 
glioblastoma, medulloblastoma, oligodendroglioma, astrocytoma, 
ganglioneuroblastoma, bladder small cell carcinoma and non-seminomatous germ cell 
tumours [165-167]. In ALT-positive tumour cells, extra chromosomal telomeric repeats 
exist in the nucleus. Another feature is the recombination-mediated lengthening of 
strands and transfer of telomere repeat sequences between sister chromosomes [168]. 
The aforementioned t-circles are increased in ALT-positive cells [169]. Associated with 
ALT, nuclear structures called promyelocytic leukaemia nuclear bodies (PML-NB) are 
found [170]. In fluorescence in situ hybridisation (FISH) staining, the telomeres of these 
tumours exhibit a large ultrabright signal and irregular length of telomeres (3 kb to more 
than 50 kb). In contrast, tumour cells with activated telomerase exhibit a homogeneous 
bright signal [171] and a similar length of 10 kb. 
 
Figure 19: Normal telomere repeat sequence (A), shelterin complex (B). End of 
replication problem (C) . Two types of telomere lengthening, the activation of telomerase 
and the recombination mediated ALT pathway (D)  [27]. 
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Figure 20: FISH showing chromosomes in the metaphase with ALT. The red fluorescent 
staining is heterogeneous with ultrabright spots  [155]. 
 
PML-NB (promyelocytic leukaemia nuclear body) 
PML-NB is a complex of PML and SP100 protein; it is a mobile structure found in the 
nucleus. The number of PML-NBs varies from five to 30, depending on the type of cell, 
the cycle phase, differentiation stage and stimuli [172]. It can be modified by small 
ubiquitin-related modifiers (SUMO) [173]. Proteins such as DAXX, TDG (thymine-
DNA glycosylase), BLM (bloom syndrome protein), CBP (CREB binding protein a co-
activator of transcription) and IKKε (inhibitor of nuclear factor kappa-B kinase ε) bind 
on PML-NBs controlled by SUMO, which has functional consequences [174].  
PML functions as a tumour suppressor and is inactivated in acute promyelocytic 
leukaemia (APL). This is due to fusion of the PML gene with the retinoic acid receptor 
alpha gene (RARα), and the fusion transcript PML-RARα delocalises PML from the 
PML-NBs [175]. PML is part of PML-NBs. In contrast to PML-NBs, PML alone is also 
found in the cytoplasm. Several tumour cells such as hepatocellular carcinomas stain 
positive for PML in the cytoplasm [176]. Reasons for this include accumulation in the 
cytoplasm, increased nuclear export or increased production of cytoplasmic isoforms of 
PML [177]. The consequences of the high proliferation of cytoplasmic PML expression 
are not yet known. However, it is a fact that cytoplasmic PML can induce the export of 
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nuclear PML into the cytoplasm and impair its ability to activate p53 [178]. 
Cytoplasmic isoforms interact with the transforming growth factor (TGF-β) pathway, 
which is involved in many cellular processes such as proliferation, differentiation and 
apoptosis [179]. It is not clear whether nuclear isoforms of PML are also able to affect 
the TGF-β pathway. Another function of cytoplasmic PML is to defend the cell against 
viral infections by colocalisation of PML and integrase interactor 1 (INI-1) with the 
retroviral preintegration complex [180]. In ALT-positive tumour cells, PML-NB form a 
shell around telomeric repeat sequences, called ALT associated PML-NB (APB) [181]. 
Components of APB are PML-NB (PML and SP100 protein, SUMO) and telomere 
repeat-associated proteins (TRF1, TRF2, PT1, RAP1) and DDR [170].  
 
Figure 21: ALT-associated PML-NB (APB). The red coloured structure represents the 
telomeric repeat sequences, surrounded by PML -NB [155]. 
 
Figure 22: A nucleus showing PML protein (green) and telomere repeat binding factor 
TRF2 (red), which is part of the shelterin complex. The yellow signals (arrows) represent 
TRF2 and PML which, together, form ALT-associated PML-NBs (AGBs) [155]. 
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1.7 Recent studies about DAXX/ATRX and ALT phenotype 
 
Jiao et al. were first to screen the exons of ten sporadic PANETs for mutations. The 
most common mutations were further investigated in 58 additional PANETs. The study 
group found 157 somatic mutations in 149 genes; the mean number of mutations was 16 
per tumour, with a range of eight to 23. The most common mutations were detected in 
the following genes: MEN1 (44.1%), DAXX (25%), ATRX (17.6%), PTEN (7.3%), TSC2 
(8.8%) and PIK3CA (1.4%). Mutations in the DAXX and ATRX gene were mutually 
exclusive. The results were then compared with clinical data. It was found that 100% of 
all patients with NETs that exhibited mutations in DAXX/ATRX genes survived for at 
least ten years, whereas patients without these mutations died within five years [70]. 
DAXX and ATRX proteins are known to be important for heterochromatin maintenance 
at telomeres [148, 151, 182]. Heaphy et al. showed a perfect correlation between the 
presence of ALT phenotype and immunohistochemical loss of DAXX/ATRX 
expression in PANETs. In addition, they examined 439 other tumours of other types 
such as glioblastoma multiforme, medulloblastomas and oligodendrogliomas. They 
found mutations in the ATRX gene that were correlated with ultrabright signals in 
telomere FISH. DAXX mutations were not detected [75]. 
 
Figure 23: ALT phenotype and nuclear loss of DAXX/ATRX expression in PANETs and 
glioblastoma multiforme. A: Ultrabright signals (arrows) in FISH in a PANET. B: Loss 
of DAXX expression with positive endothelial cells as internal control (arrowheads)  in a 
PANET. C: Ultrabright signals (arrows) in FISH in a glioblastoma multiforme. D: Loss 
 38 / 95 
 
of ATRX expression in a glioblastoma multiforme. Positive endothelial cells 
(arrowheads) served as positive internal control.  
 
Chen et al. obtained a similar result, showing a loss of DAXX/ATRX expression in 
41.4% of PANETs. In 80% of rectal NETs, 60% of gastric NETs and 27% of duodenal 
NETs there was also a loss of expression of DAXX/ATRX. Je et al. revealed that 
alterations of the ATRX gene are not common in gastric, colorectal or prostate cancers. 
Hence these findings suggest that loss of DAXX/ATRX is special for NETs [183]. 
There was no loss of expression in these two stainings in normal pancreatic tissue and 
ductal adenocarcinomas of the pancreas. In addition, the study group reported that the 
status of DAXX immunoreactivity was positively associated with the Ki-67 index 
[184]. A Chinese study included 37 Chinese patients with PANETs, five of which were 
insulinomas. They identified 133 somatic mutations in eight different genes by using 
Sanger sequencing with the following frequencies: DAXX/ATRX (54%), KRAS (10.8%), 
MEN1 (35.1%), mTOR pathway genes PTEN and TSC2 (54%), SMAD4/DPC (2.7%), 
TP53 (13.5%) and VHL (40.5%). In particular for insulinomas, the following genes 
were showed to have mutations: ATRX, DAXX, MEN1, PTEN, TSC2 and VHL. The 
study group correlated the results with clinical data and found that patients with 
mutations in KRAS and DAXX/ATRX  had a shortened overall survival [185]. Marinoni 
et al. confirmed the importance of DAXX/ATRX mutations in PANETs and the 
correlation with ALT phenotype. In addition, they found a relationship between these 
results and CIN (chromosome instability). CIN was defined as the total number of gains 
and losses of eight or more in conventional comparative genomic hybridisation (CGH) 
data and 20 or more in array CGH. To date, it is unclear whether CIN induces ALT or 
whether ALT is part of CIN. Concerning the clinical outcome, the study by Marinoni et 
al. generated different results to those by Jiao et al. In detail, they reported that ALT-
positive tumours exhibited a significantly decreased relapse-free survival as well as a 
reduced tumour-specific survival. In correlation with DAXX/ATRX loss, a decreased 
relapse-free survival was found, but not a shortened tumour-specific survival [186]. One 
reason for this discrepancy could be the different collectives. While Jiao et al. examined 
tumours that had already metastasised, Marinoni et al. recruited PANETs with a benign 
behaviour.  
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Another study concerning liver metastasis of NETs (48% PANETs, 52% NETs of the 
GI tract) explored the correlation between ALT phenotype and clinical data. Among 
metastases of gastrointestinal NETs, 4% were ALT-positive; 56% of metastases of 
PANETs exhibited the ALT phenotype. This study group reported that the ALT 
pathway is associated with an increased overall survival (132 vs. 71 months) [187]. 
 
Table 7: Recent studies reporting DAXX/ATRX mutations/loss of expression in PANETs. 
ALT = alternative lengthening of telomeres, IHC = immunohistochemistry, MEN1 = 
multiple endocrine neoplasms type 1, CIN = chromosome instability .
Reference Method Number of 
PANETs 
DAXX 
mutation/ 
loss of 
expression 
ATRX 
mutation/ 
loss of 
expression 
Associated 
with 
Clinical 
outcome 
Jiao [70] Exome 
sequencing 
 
68 25% 17.6%  Better 
outcome 
De wilde 
[76] 
IHC 50 (28 
MEN1) 
6% 2% ALT 
phenotype 
Larger in 
diameter, 
higher 
grade 
 
Heaphy 
[75] 
Sequencing/ 
IHC 
39 24% 22% ALT 
phenotype 
No 
association 
 
Chen 
[184] 
IHC 70 25% 15.7% 
 
Ki-67 
index 
 
Yuan 
[185] 
Sequencing 37 54% 11% 
 
 Worse 
Marinoni 
[186] 
IHC/ 
sequencing 
 
92 25% 18% ALT and 
CIN 
Worse 
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2. Aim of thesis 
 
Neuroendocrine tumours are rare neoplasms with an incidence of 2-4 per 100,000 
population [3], which is increasing at a rate of 3-10% per year, depending on the 
subtype [4]. In early stages, surgical resection is curative, but at the time of diagnosis, 
50% of patients already have distant metastases [8, 9]. The prognosis in such cases is 
three years for G1 graded tumours and 24 months for G2 graded tumours; for NECs, the 
median survival is 3-10 months. Several drugs are available which improve the 
prolonged survival time for 10-15 months. Until now, little is known about the 
biological mechanisms of this kind of tumour. Further investigations are necessary to 
find new targets for therapy in advanced stages. DAXX and ATRX mutations were 
recently found in 43% of PANETs [70]. These mutations are combined with an ALT 
phenotype [75]. In our study, we examine the expression of DAXX/ATRX in 
insulinomas and NETs of the small intestine by using immunohistochemistry. In 
addition, we investigate tumours for the presence of ALT phenotype by FISH. Our aim 
is to examine the significance of DAXX/ATRX expression and ALT phenotype in 
insulinomas, which has been investigated in PANETs, but only for a small number of 
insulinomas. We also address this question in NETs of the small intestine, which has 
not been examined at all. In addition, we explore the relationship between clinical data 
and our findings.  
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3. Material and methods 
3.1 Subject/case selection 
Insulinomas 
126 cases with well-differentiated insulinomas were included in our study. 62 cases 
were recruited from the archives of the Department of Pathology of the University 
Hospital in Zurich (Switzerland), Düsseldorf (Germany), Kiel (Germany) and Verona 
(Italy). All patients underwent surgery between 1975 and 2006. The other 64 cases were 
from the consultation archives of the Department of Pathology of the University 
Hospital in Kiel (Germany), G. Klöppel. The diagnosis was based on the WHO 
classification of 2010. 
The cohort consists of 120 primary tumours, 20 of which exhibited malignant 
behaviour. Lymph node metastases and liver metastases were available for four primary 
tumours. Furthermore, two lymph node metastases and four liver metastases were 
available despite the absence of tissue of the primary. 78 patients were female, 46 were 
male (no information about gender was provided in two cases). The mean age was 50 
years, with a standard deviation of 17. The oldest patient was 84, and the youngest 16. 
The mean size of the tumour was 2.1 cm. 
Demographic features of patients with 
insulinoma 
 
 
 Mean (percentage) Range 
   
Female 78 (62%)  
Male 46 (37%)  
Not known 2 (1%)  
Age 50 years 16-84 years 
Tumour 
size 
2.1 cm 0.8-10 cm 
Table 8: Demographic features of patients with insulinomas. 
siNETs 
135 cases with well-differentiated neuroendocrine tumours of the ileum were recruited 
from the archives of the Department of Pathology of the University Hospital in 
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Tübingen, Düsseldorf, Marburg and TU München (Germany). All tumours were 
diagnosed based on the WHO classification of 2010. Tissue of primary tumours of 127 
patients was available. A total of 74 lymph node metastases and 15 liver metastases 
were available. 50 were female, 56 male; no information about gender was provided for 
the others. The mean age was 58 years; the youngest patient was 20, the oldest 87. 
Demographic features of patients with 
neuroendocrine tumours of the small intestine 
 
 
 Mean (percentage) Range 
   
Female 50 (37%)  
Male 56 (41%)  
Not known 29 (22%)  
Age 58 years 20-87 years 
Tumour 
size 
1.9 cm 0.2-8 cm 
Table 9: Demographic features of patients with neuroendocrine tumours of the small 
intestine.  
UICC stage 
Number of patients 
 
Stage I 7 
Stage II A 6 
Stage II B 5 
Stage III A 1 
Stage III B 35 
Stage IV 52 
Not known 29 
Table 10: UICC stage of patients with neuroendocrine tumours of the small intestine. 
UICC = Union of International Cancer Control.  
The study design was approved by the Local Ethics Committee in Tübingen 
(022/2014BO1).  
3.2 Immunohistochemistry (IHC) 
 
Immunohistochemistry (IHC) was established by Albert Coons in 1941, and is now an 
important part of pathology. IHC is an immunological method that uses binding 
between antibody and antigen. First, a primary antibody is used to bind on an epitope 
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consisting of a sequence of five to ten amino acids. Next, the antibody-antigen binding 
sites are detected either directly or indirectly by using a second antibody. When a 
further signal enhancement is required, the secondary antibody carries biotin which 
binds to a complex of avidin and a biotin carrying enzyme. In this case, more marker 
molecules are involved and the signal is enhanced. 
For our study, we used antibodies to detect ATRX (Sigma/ # HPA001906) and DAXX 
(Sigma/# HPA008736). 
Protocol for immunostaining ARTRX and DAXX: 
Preparation 
Deparaffination: 
 3x 10 min xylol 
 2x 3 min 100% EtOH 
 2x 3 min 98% EtOH 
 1x 3 min 75% EtOH 
 1x 5 min 75% EtOH with 3% of H2O2 (20 ml 30% H2O2 in 180 ml 75% EtOH) 
 5 min washing in dH2O 
Pre-treatment 
Ci pH6 or TEC pH9 5 min 
Anneal slides for 20 min 
Dip slides briefly in dH2O 
2x 3 min in wash buffer 
TECAN 
Put all slides into machine 
Fill buffer cuvette  
1. Block, 2. secondary AK, 3. conjugate (HRP Polymer) 
200 µl per slide 
Programme: 
 Wash buffer 5 min 
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 Block 5 min 
 AK is pipetted (30 min) 
 Wash buffer 5 min 
 Secondary AK 30 min 
 Wash buffer 5 min 
 Conjugate 30 min 
 Wash buffer 5 min 
 DAB 2x 5 min 
 Wash buffer 5 min 
End of process 
Put slides from cover plates into dH2O 
Counterstain with Papanicolaou for 15 min 
3x wash in dH2O 
Pan slides in EtOH/ammonium (200 ml 70% EtOH+6 ml NH3) 
1x 70% EtOH 2 min 
1x 80% EtOH 2 min 
2x 96% EtOH 2 min 
4x 100% EtOH 2min 
2x xylol 2 min  
Put into embedding machine 
 
 
Evaluation of immunohistochemical findings 
Three core biopsies of each tissue block were scored in order to avoid sampling errors. 
Two pathologists independently scored the immunohistochemistry staining. The tissue 
was only classified if there was a positive internal control, such as lymphocytes or 
stromal cells. If there was no positive internal control, staining was repeated, but this 
time the whole tissue was used. If there was still no positive internal control, the case 
was determined as not assessable (n.a.). It was noted whether there was nuclear or/and 
 45 / 95 
 
cytoplasmic staining. Only nuclear staining was counted. No positive cells or less than 
10% stained tumour cells were rated as loss of expression. If between 10% and 80% of 
the tumour cells were stained positive, staining was called heterogeneous. An excess of 
80% of stained tumour cells was rated as positive.  
3.3 Fluorescence in situ hybridisation (FISH)  
 
Fluorescence in situ hybridisation, first used in 1980 [188], is a method for detecting 
sequences of DNA and RNA in metaphase and interphase cells by using probes with 
complementary sequences. The probes are either directly marked with a fluorescence 
stain or digoxigenin/biotin labelled probes are used, detected by fluorochrome labelled 
anti-digoxigenin or anti-biotin antibodies. These are plasmids, cosmids, phages, YACs 
(yeast artificial chromosomes) or complete chromosomes. For detection, several 
fluorochrome stains are provided for single colour FISH, Multiplex-FISH or SKY-FISH 
(Spectral Karyotyping), 24-colour karyotyping to detect structural or numerical 
aberrations [189]. Either fixed permeabilised cells or formalin-fixed paraffin-embedded 
slides can be used for this technique. FISH is applied for the purpose of research and 
diagnosis. With this technique, it is possible to: 
 Locate genes and DNA sequences to detect translocations, deletions, inversions and 
insertions. One example of a translocation is the Philadelphia chromosome in chronic 
myeloid leukaemia, where there is a breaking point in chromosome 22 and this part 
fuses with chromosome 9. 
 Provide evidence of RNA to detect gene expression. 
 Provide evidence of pathogenic germ in tissues. 
 Identify chromosomes. In prenatal diagnosis, for example, the Down’s syndrome can 
be detected by proving a third chromosome 21. 
 Identify amplifications, for example, the Her2 coding ERBB2 gene in carcinoma of 
the breast. This is used in routine diagnostics when immunohistochemistry staining 
of Her2 is uncertain. 
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Figure 24: FISH technique: the target DNA is denaturated and then hybridi sed with the 
complementary PNA (peptide nucleic acid). In our study, the PNA was complementary to 
the mammalian telomere repeat sequence.  
For our study, formalin-fixed, paraffin-embedded tissue microarrays were used. This 
FISH was performed at the Institute for Pathology, University of Bern (Switzerland). 
TMAs were hybridised with the complementary peptide nucleic acid to mammalian 
telomere repeat sequence CCCTAACCCTAACCCTAA (N- to C-terminus). This was 
done per protocol as listed below. The slides were counterstained with DAPI (4’, 6-
diamidino-2-phenylindole dihydrochloride), which stains the nucleus. In order to detect 
telomere signals, fluorescein isothiocyanate (FITC) with anti-digoxigenin binds on the 
digoxigenin-labelled probe. A Zeiss Axio Imager M2 microscope with appropriate 
emission filters was used to analyse the samples.  
 
Protocol for telomere FISH 
Pre-treatment: 
1 h 60°C ageing 
3x xylene 10 min 
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100% EtOH 3x 2 min 
Air dry 
Immerse slides in 100 mM Tris/ 50 mM EDTA PH 7.0 (92.8°C for 15 min) 
PBS rinse 
250-300 µl 
Digest all 37°C, pepsin 1:2, 14 min 
PBS rinse 
Dehydrate in EtOH 70%, 85%, 95%, 100% RT, 2 min each 
Air dry 
Probe preparation:  
ERG: 10 µl HB+2 µl Cot-1+2 µl Probe-Bio+2 µl Probe-Dig,   
 denat. 73°C  5min 
Hybridisation: 
Place 15 µl probe mix on slide for 18x18 mm coverslip 
Rubber cement edges to maintain probe concentration 
Place in crocodile 94°C for 3 min, 37°C overnight 
Post-hybridisation wash: 
Immerse slides in 2x SSC: RT for a few minutes, let coverslip swim off   
       75°C for 6 min 
Detection: 
Rinse the slides in 0.5x SSC, RT, 3x 2 min 
CAS-Block (10% normal goat serum), RT 
FITC anti-Dig/594 SAV, 1:500, 1 h 
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Rinse slides in 0.5x SSC, RT, 3x 2 min 
 
Evaluation of telomere FISH 
Two pathologists independently gave scores to the TMAs. In order to classify as ALT-
positive tumour cells, the following criteria had to be met: large heterogeneous 
ultrabright signals located in the nucleus of the tumour cells and coexistent normal 
telomere signals in surrounding lymphocytes and stromal cells. Tumour cells with 
normal telomere signals were scored as ALT-negative. Cores of TMAs without any 
signal were rated as not assessable (n.a.). 
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3.4  Statistical analysis 
 
Statistical analysis was performed using SPSS (version 22.01). The Pearson chi-squared 
test was used to compare DAXX/ATRX and ALT phenotype with biological behaviour. 
The Mann Whiteney U test was used to test for correlation of DAXX/ATRX loss and 
ALT phenotype with tumour size. The relationship between loss of DAXX/ATRX or 
ultrabright signals in FISH and overall survival was examined using the log-rank test 
depicted as Kaplan- Meier curve. P values below 0.05 were denoted as statistically 
significant.  
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4. Results 
HE staining 
All tissue microarrays (TMAs) were stained with haematoxylin & eosin (HE) to identify 
the morphology of the tumour for recognising tumour cells in DAXX and ATRX 
staining and to distinguish tumour cells from other cells such as lymphocytes in the 
FISH.  
Telomere FISH in normal cells 
Lymphocytes and pancreas acini exhibit normal telomere signals. A few small round 
signals are detectable in each cell. The signals are slight and have a homogeneous 
distribution.  
 
Figure 25: Lymphocytes (A) and pancreas acini (B)  with homogeneous green detecting 
telomeres. A, B: 1000x telomere FISH.  
  
B A 
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4.1 Insulinomas 
4.1.1 ALT phenotype 
 
There were four cases (3%) of insulinomas that exhibited ultrabright signals. All cases 
were insulinomas with malignant behaviour. In three of these cases tissue of the primary 
and the metastasis were available. One ALT-positive case was a liver metastasis; the 
tissue of the primary was not available. All cases were associated with loss of 
expression of DAXX/ATRX. One of them (25%) was correlated with a loss of DAXX 
expression; the other three (75%) were correlated with a loss of ATRX expression. The 
mean age of patients with ALT-positive tumours was 52 years, similar to the mean age 
of all patients with insulinoma. Three were female and one was male. The mean tumour 
size in ALT-negative cases was 2.1 cm and 5.5 cm in ALT-positive cases. The biggest 
tumour measured 8 cm. The cases with ALT-positive phenotype are listed below (Table 
12). 
FISH normal ub n.a. 
 Primary tumour 74 (61%) 3 (3%) 43 (36%) 
 Lymph node metastasis 2 (40%) 2 (40%) 1 (20%) 
 Liver metastasis 1 (13%) 4 (40%) 3 (37%) 
 
Table 11: FISH results of insulinomas. FISH  = fluorescence in situ hybr idisation, ub = 
ultrabright signals, n.a. = not assessable.  
Table 12: All insulinoma cases with the ALT phenotype. P =Primary, LNM = lymph node 
metastasis, LM = liver metastasis, ub  = ultrabright signal in FISH, norm = normal 
expression of DAXX/ATRX, loss = loss of DAXX/ATRX expression, x = no tissue, f = 
female, m = male. 
Case  
Nr 
FISH 
P 
FISH 
LNM 
FISH 
LM 
DAXX 
P 
DAXX 
LNM 
DAXX 
LM 
ATRX 
P 
ATRX 
LNM 
ATRX 
LM Gender Age 
Tumour 
size 
59 ub ub ub norm norm norm loss loss loss f 56 8 
57 ub x ub norm x norm loss x loss f 
 
63 1.7 
61 ub ub ub norm loss loss norm norm norm f 55 8 
56 x x ub x x norm x x loss m 36 4.5 
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Figure 26: Distribution of cases with ALT phenotype. n.a. = not assessable.  
The following images show cases classified as ALT-positive.  
 
Figure 27: Case number 59: primary tumour of a 56-year-old woman with a tumour size 
of 8 cm. Loss of ATRX expression with positive internal control and normal DAXX 
expression. The telomere FISH shows heterogeneous ultrabright signals. A: HE 400x, B: 
ATRX 400x, C: DAXX 400x, D: FISH 1000x . 
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Figure 28: Case number 59: lymph node metastasis of the primary tumour shown above. 
The metastasis also shows a loss of ATRX expression and DAXX show ed a strongly 
nuclear expression in the tumour cells, neighbouring strongly positive lymphocytes. The 
telomere FISH is positive for the ALT phenotype. A: HE 400x, B: ATRX 400x, C: DAXX 
400x, D: FISH 1000x. 
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Figure 29: Case number 59, liver metastasis. Loss of ATRX expression with 
neighbouring positive lymphocytes. DAXX expression is normal. FISH reveals spotted 
ultrabright signals. A: HE 200x, B: ATRX 400x, C: DAXX 400x, D: FISH 1000x. 
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Figure 30: Case number 57: primary tumour of a 63-year-old woman with a tumour size 
of 1.7 cm. Tumour cells with loss of ATRX expression and normal DAXX staining. The 
telomere FISH shows heterogeneous ultrabright signals, classified as positive for the 
ALT phenotype. A: HE 200x, B: ATRX 200x, C: DAXX 200x, D: FISH 1000x . 
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Figure 31: Case number 57, liver metastasis. As the primary tumour, the liver metastasis 
also shows a loss of ATRX expression. DAXX was positive in about 85% of the tumour 
cells, classified as normal expression. In the telomere FISH , ultrabright heterogeneous 
signals typical for ALT phenotype were present. A: HE 200x, B: ATRX 200x, C: DAXX 
200x, D: FISH 1000x.  
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Figure 32: Case number 61, primary tumour of a 55-year-old female with a tumour size 
of 8 cm. In the primary tumour, ATRX and DAXX staining were classified as normal.  
The telomere FISH was ALT-positive. A: HE 400x, B: ATRX 400x, C: DAXX 200x, D: 
FISH 1000x. 
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Figure 33: Case number 61, lymph node metastasis.  ATRX staining was normal and 
DAXX expression, different to the primary, was lost in the tumour cells. FISH signals 
were positive for ALT. A: HE 400x, B: ATRX 400x, C: DAXX 400x, D: FISH 1000x.  
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Figure 34: Case number 61, liver metastasis. Similar to the lymph node metastasis ,  the 
tumour cells stained positive for ATRX and showed a loss of DAXX expression. FISH 
signals were strongly heterogeneous with spotted ultrabright signals. A: HE 400x, B: 
ATRX 400x, C: DAXX 400x, D: FISH 1000x.  
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Figure 35: Case number 56, liver metastasis of a 36-year-old man with a primary tumour 
of 4.5 cm in diameter.  ATRX expression was lost in tumour cells neighbouring positive 
liver cells with background staining. DAXX expression was normal. Telomere FISH 
revealed spotted ultrabright signals. A: HE 200x, B: ATRX 200x, C: DAXX 200x, D: 
FISH 1000x.  
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One case, a primary tumour of a 79-year-old woman with a tumour size of 3 cm, was 
normal for DAXX and ATRX expression, but yielded a different distribution of 
telomere signals in FISH to ALT-positive or ALT-negative cases. As the figure below 
shows, there are bright homogeneous signals of the same size and some spotted bigger 
signals, which are somehow smaller than ALT-positive signals, but brighter than normal 
signals. For this reason, we classified this case as unclear.  
Figure 36: Case number 102,  insulinoma of a 79-year-old woman with a size of 3 cm. 
The tumour had not metastasised. The telomere signal is predominantly bright and 
homogeneous, but also shows sporadic spotted ultrabright  signals. This case was 
classified as not assessable.  
 
 
 
 
Figure 37: Case number 102, the ATRX and DAXX expression is normal with a strongly 
nuclear positivity.  A: HE 200x, B: ATRX 200x, C: DAXX 200x.  
A B C 
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4.1.2 Loss of DAXX expression 
 
Only one (0.8%) of the 126 insulinomas yielded a loss of DAXX expression. DAXX 
staining was normal for the primary tumour, but a loss of expression was yielded in the 
lymph node and liver metastasis. The primary, the lymph node and the liver metastasis 
showed ultrabright abnormal signals in FISH. The ATRX expression was normal in the 
primary and liver metastasis; the lymph node metastasis was classified as 
heterogeneous. This patient was female, 55 years old, and had an 8 cm sized tumour. 
DAXX Normal Heterogeneous Loss n.a. 
Primary tumour 93 (77%) 0 0 27 (23%) 
Lymph node metastasis 3 (60%) 0 1 (20%) 1 (20%) 
Liver metastasis 4 (50%) 1 (13%) 1 (13%) 2 (25%) 
Table 13: DAXX results in insulinomas.  n.a. = not assessable.  
Table 14: A single case with loss of DAXX expression. P  = primary, LNM = lymph node 
metastasis, LM = liver metastasis, norm = normal expression of DAXX/ATRX, het = 
heterogeneous expression of DAXX/ATRX, loss = loss of expression of DAXX/ATRX, 
ub = ultrabright signals in FISH, f  = female.  
 
Figure 38: Distribution of cases with loss of DAXX expression.  n.a. = not assessable.  
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Case 
Nr. 
DAXX 
P 
DAXX  
LNM 
DAXX 
LM 
ATRX 
P 
ATRX 
LNM 
ATRX 
LM 
FISH 
P 
FISH 
LNM 
FISH 
LM Gender Age 
Tumour 
size 
61 norm loss loss norm het norm ub ub ub f 55 8 
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4.1.3 Loss of ATRX expression 
 
Four cases (3%) showed a loss of expression of ATRX. Two of these had lymph node 
and/or liver metastasis. In two of the cases, tissue of the liver metastasis was available, 
but not of the primary. There was no simultaneous loss of DAXX expression. One case 
did not correlate with an ALT phenotype. This case was a liver metastasis for which no 
tissue of the primary tumour was available. The mean age was 59 years. The average 
size of the primary tumour was 4.1 cm compared to the mean tumour size of all 
insulinomas, which was 2.1 cm.  
ATRX Normal Heterogeneous Loss n.a. 
Primary tumour 84 (70%) 0 2 (2%) 34 (28%) 
Lymph node metastasis 4 (80%) 0 1 (20%) 0 
Liver metastasis 2 (25%) 0 4 (50%) 2 (25%) 
Table 15: ATRX results in insulinomas. n.a. = not assessable.  
ase 
Nr. 
ATRX 
P 
ATRX 
LNM 
ATRX 
LM 
DAXX 
P 
DAXX 
LNM 
DAXX 
LM 
FISH 
P 
FISH 
LNM 
FISH 
LM Gender Age 
Tumour 
size 
59 loss loss loss norm norm norm ub ub ub f 56 8 
57 loss x loss norm x norm ub x ub f 63 1.7 
58 x x loss x x norm x x norm m 82 2.5 
56 x x loss x x norm x x ub m 36 4.5 
Table 16: All cases with loss of ATRX expression. P = primary, LNM = lymph node 
metastasis, LM = liver metastasis, norm = normal expression of DAXX/ATRX, normal 
FISH signal, loss = loss of expression of DAXX/ATRX, ub = ultrabright FISH signals = 
no tissue, n.a. = not assessable.  
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Figure 39: Case number 58, liver metastasis of an 82-year -old man with a tumour size of 
the primary tumour of 2.5 cm. ATRX expression is lost in tumour cells, DAXX 
expression is normal. FISH was classified as normal telomere signal. A: HE 200x, B: 
ATRX 200x, C: DAXX 200x, D: FISH 1000x
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4.1.4 Correlation between the results and clinical data 
4.1.4.1 Correlation between our results and biological behaviour 
A total of 59 cases were investigated for DAXX expression and biological behaviour. 
47 cases showed benign behaviour and 12 cases were malignant. There was one case 
with loss of DAXX expression, which was malignant. 
 
Figure 40: Malignant and benign insulinomas with a loss of DAXX expression.  
A total of 59 cases were investigated for loss of ATRX expression and biological 
behaviour. 13 cases were malignant, 46 were benign. All four cases with loss of ATRX 
expression showed malignant behaviour. 
 
Figure 41: Malignant and benign insulinomas with a loss of ATRX expression.  
Altogether, 56 cases with assessable expression of DAXX and ATRX were investigated 
for clinincal behaviour. 11 cases were malignant; 45 were benign. 5 cases showed loss 
of either DAXX or ATRX expression, all of them were malignant insulinomas. None 
was benign. 
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Figure 42: Malignant and benign insulino mas with ultrabright signals in telomere FISH.  
In total 60 cases were assessable for telomere FISH signals. 49 cases  of them were 
benign insulinomas; 11 cases showed malignant behaviour. 4 cases exhibit ultrabright 
signals in FISH, these cases were all malignant. 
 
Figure 43: Number of cases of ALT phenotype, DAXX/ATRX expression loss in 
malignant insulinomas.  
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4.1.4.2 Correlation between our results and prognosis 
 
A total of 56 cases (45 with benign behaviour, 11 with malignant behaviour) were 
investigated for correlation between our results and clinical data. Cases with no clinical 
information or without fully assessable data were excluded. 51 patients had insulinomas 
with normal expression for DAXX/ATRX. Five patients had insulinomas that showed a 
loss of DAXX/ATRX expression. By using the log-rank test, we revealed a correlation 
between loss of DAXX/ATRX expression and a worse outcome with a significance of p 
= 0.012. There was no significance (p = 0.129) between ultrabright signals and a worse 
outcome. One explanation could therefore be the small number of cases with ultrabright 
signals in FISH.  
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Figure 44: Kaplan Meier curve showing overall survival time of patients with 
insulinomas with DAXX/ATRX loss and normal expression of DAXX/ATRX. Green: loss 
of DAXX/ATRX. Blue: normal DAXX/ATRX expression.  
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4.2 Neuroendocrine tumours of small intestine 
 
4.2.1 ALT phenotype 
 
Only one case of 135 showed heterogeneous and ultrabright signals in telomere FISH. 
The patient was 67 years old; the primary tumour measured 6 cm. The primary tumour 
was normal in FISH, but the lymph node metastasis showed an ALT-positive FISH 
signal. DAXX and ATRX expression was normal. 
FISH Normal ub n.a. 
Primary tumour  117 (92%) 0 10 (8%) 
Lymph node metastasis 64 (86%) 1 (1%) 9 (12%) 
Liver metastasis 14 (93%) 0 1 (7%) 
Table 17: FISH results in NETs of the small intestine. ub = ultrabright signals , n.a. = not 
assessable.  
Table 18: All cases with ALT phenotype. P = primary, LNM = lymph node metastasis, 
LM = liver metastasis, norm = normal, ub = ALT phenotype, n.a. = not assessable, x = no 
tissue. 
Figure 45: Distribution of cases with ultrabright signals in telomere FISH.  n.a. = not 
assessable.  
Case 
Nr. 
FISH 
 P 
FISH 
LNM 
FISH 
LM 
DAXX 
P 
DAXX 
LNM 
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ATRX 
LM Gender Age 
Tumour 
size 
I 123a norm ub x norm norm x norm norm x n.a. 67 6 
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Figure 46: Case number 123a, primary tumour. ATRX staining was normal. More than 
80% of tumour cells were positive for DAXX. FISH was classified as normal. A: HE 
200x, B: ATRX 200x, C: DAXX 200x, D: FISH 1000x.  
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Figure 47: Case number 123a, lymph node metastasis. ATRX and DAXX were strongly 
positive in tumour cells. FISH showed heterogeneous ultrabright signals, classified as 
ALT-positive. A: HE 200x, B: ATRX 200x, C: DAXX 200x, D: FISH 1000x.   
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4.2.2 Loss of DAXX expression 
 
There was one patient with a loss of DAXX expression. This patient was a 50-year-old 
woman with a tumour size of 0.8 cm and no metastasis. ATRX staining and telomere 
FISH were both detected as normal. 
DAXX Normal Heterogeneous Loss n.a. 
Primary tumour 102 (80%)  18 (14%) 1 (0.7%) 6 (5%) 
Lymph node 
metastasis 
69 (93%) 1 (1%) 0 4 (6%) 
Liver metastasis 14 (93%) 0 0 1 (7%) 
Table 19: DAXX results in NETs of the small intestine.  n.a.  = not assessable.  
Case 
Nr. 
DAXX 
P 
DAXX 
LNM 
DAXX 
LM 
ATRX 
P 
ATRX 
LNM 
ATRX 
LM 
FISH 
P 
FISH 
LNM 
FISH 
LM Gender Age 
Tumour 
size 
I 003 loss x x norm x 0 norm x x f 50 0.8 
Table 20: One case with a loss of DAXX expression. P = primary, LNM = lymph node 
metastasis, LM = liver metastasis,  norm = normal ATRX expression/normal  FISH: loss = 
loss of expression, n.a. = not assessable, x  = no tissue, f = female. 
Figure 48: Distribution of cases with a loss of DAXX expression.  n.a. = not assessable.  
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Figure 49: Case number 003, primary tumour. Less than 10% of tumour cells are positive 
for DAXX, and therefore classified as a loss of DAXX expression. ATRX was stained 
normal, and telomere FISH showed slight ly homogeneous signals. A: HE 200x, B: ATRX 
200x, C: DAXX 200x, D: FISH 1000x.  
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Figure 50: Case number 33a, primary tumour with heterogeneous DAXX staining and 
normal ATRX staining. FISH was classified as normal. A: HE 200x, B: ATRX 200x, C: 
DAXX 200x, D: FISH 1000x.   
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4.2.3 Loss of ATRX expression 
 
There was no case with a loss of ATRX expression. 
ATRX Normal Heterogeneous Loss n.a. 
Primary tumour 120 (94%) 0 0 7 (6%) 
Lymph node 
metastasis 
67 (91%) 0 0 7 (9%) 
Liver metastasis 13 (87%) 0 0 2 (13%) 
Table 21: ATRX results in NETs of the small intestine. n.a.  = not assessable.  
Figure 51: Distribution of cases with a loss of ATRX. n.a. = not assessable.  
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5. Discussion 
 
Neuroendocrine tumours (NETs) arise from neuroendocrine cells. Most NETs are found 
in the pancreas (34.2%); the second most common location is the small intestine 
(25.8%) [1]. The incidence of 2-4 per 100,000 population is increasing by 3-10% per 
year, depending on the subtype [3, 4]. One reason for this could be the improvement of 
diagnostic methods. Nevertheless, 50% of patients already had distant metastases at the 
time of diagnosis [8, 9]. For patients in the early stages, surgical resection is a curative 
therapy. In advanced disease, the following drugs are available: somatostatin analogues, 
targeted agents such as mTOR inhibitors, inhibitors of angiogenesis and interferon α. 
Somatostatin analogues such as ocreotide are administered when somatostatin receptors 
on the tumour cells are proved by SRS. In functional NETs, it is useful to prevent 
clinical symptoms, but recurrance of the symptoms are common [89]. A stabilisation of 
tumour growth is seen in 24-57% of cases [134]. The mTOR inhibitor everolimus is 
approved by the FDA for PANETs, but not for siNETs [137]. In PANETs, the 
prolonged survival time is 10 vs. 4.6 months compared to the placebo [79]. Inhibitors of 
angiogenesis such as sunitinib, a tyrosin kinase inhibitor, exhibited a longer survival 
time of 10.2 vs. 5.4 months compared to a placebo group [96]. In conclusion, a better 
understanding of the biological mechanisms of this tumour type is necessary in order to 
find drugs for targeted therapy. Recent studies reported that about 40% of sporadic 
insulinomas show mutations in the MEN1 gene [70]. MEN1 is a tumour suppressor 
gene; mutations in this gene are a hallmark of the autosomal dominant disease MEN1. 
15% of PANETs harbour mutations in the mTOR pathway (PTEN, TSC2, PIK3CA) 
[70]. Inhibitors of this pathway have already been approved for advanced PANETs 
[137]. Jiao et al. recently determined that 45% of PANETs show mutations in 
DAXX/ATRX genes. Both DAXX and ATRX proteins are involved in remodelling 
chromosomes. Studies investigating these genes [70, 75, 184] and our results show that 
mutations/loss of expression in these genes are mutually exclusive. A Chinese study 
confirmed that alterations in DAXX/ATRX genes (54%) and genes of the mTOR 
pathway (54%) are common in PANETs. They also found mutations in KRAS (10.85), 
SMAD4/DPC (2.7%) and VHL (40.5%). In their study cohort, five insulinomas were 
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included with the following frequencies of gene mutations: 20% ATRX, 20% DAXX, 
40% MEN1, 20% PTEN and 40% TSC2 [185]. In addition, Heaphy et al. found a perfect 
correlation between loss of DAXX/ATRX expression and ultrabright signals in 
telomere FISH, established as a hallmark for ALT phenotype [75]. ALT is an alternative 
mechanism of the cell for telomere maintenance. 85% of tumours activate the 
telomerase. Examples of tumour types that use the ALT pathway are osteosarcomas, 
soft tissue sarcomas, glioblastomas, medulloblastomas, oligodendrogliomas and 
astrocytomas [165-167]. Features of the ALT pathway are extrachromosomal telomeres, 
the exchange of telomeres between sister chromosomes, increased t-circles and the 
presence of PML-NBs [168-170]. It has been suggested that the DAXX and ATRX 
complex binds on G-rich regions, such as telomere repeats, and deposits the histone 
H3.3. The consequences of this are not yet understood [147-151]. 
So far, very few cases of insulinomas have been investigated for DAXX/ATRX 
mutations, and the reported studies did not include any NETs of the small intestine, 
which are the second most common NETs. Our purpose was to examine these subtypes 
for expression of DAXX/ATRX and to explore the relationship with ALT phenotype 
and clinical data.  
 
In insulinomas, we found one case (0.8%) with a loss of expression of DAXX and four 
cases (3%) with a loss of ATRX expression. These losses were exclusive; we detected 
no cases with a loss of expression in both types of staining. This finding is in 
accordance with several other studies [70, 75, 185, 186]. In telomere FISH, we found 
four cases (3%) with ultrabright heterogeneous signals. In line with Heaphy et al., we 
detected a 100% correlation between ALT phenotype and DAXX or ATRX loss 
expression. One case (25%) yielded a loss of DAXX expression; three cases (75%) had 
a loss of ATRX. One difficult case, a primary tumour of a 79-year-old woman with a 
tumour size of 3 cm which was normal for DAXX and ATRX expression, showed a 
different distribution of the telomere signals in FISH to ALT-positive or ALT-negative 
cases. The signals were bright, evenly distributed, homogenous and of the same size. In 
addition, a number of spotted bigger signals were detected that were somehow smaller 
than ALT-positive signals, but brighter than normal signals. It is unclear whether this 
tumour was able to activate telomerase or whether it was positive for ALT and also had 
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activated telomerase. Another explanation could be that this tumour started to activate 
the ALT phenotype, so the signals get brighter and the distribution will become 
increasingly heterogeneous. For this reason, we classified this case as unclear.  
In addition, we found one case with a loss of ATRX and a normal telomere signal in 
FISH. This case was an 82-year-old man with a liver metastasis, with the primary 
tumour measuring 2.5 cm. One explanation of this finding could be that the tumour 
already had a loss of ATRX and the ALT mechanism will be activated subsequently, 
but was not yet detectable [186]. Moreover, we detected no case with loss of DAXX 
expression and normal FISH signals. Another aim of this thesis was to investigate the 
correlation between our results and the clinical data. We found a strongly significant 
correlation (p< 0.001) between DAXX/ATRX loss and malignant behaviour. This result 
conforms with the study group around de Wilde [76]. Our finding also matches the 
study involving metastases of NETs, where they found 56% ALT-positive cases in 
metastases of PANETs [187]. In addition, we revealed a correlation between 
DAXX/ATRX loss and a greater tumour size with a strong significance (p= 0.005). This 
was also shown by the study group around Heaphy [75] and De Wilde [76]. Concerning 
the prognosis, we found an association between DAXX/ATRX loss and a shortened 
overall survival time (p= 0.012). This finding is in agreement with the finding of Yuan 
et al. [185]. Marinoni et al. came to the conclusion that DAXX/ATRX loss predicted a 
decreased relapse-free survival; no shortened tumour-specific survival was observed 
[186]. In contrast, Jiao et al. revealed that patients with PANETs that contained altered 
DAXX/ATRX mutations yielded a longer survival time. This discrepancy can be ascribed 
to a different cohort, which included metastasised PANETs of patients with palliative 
therapy [186]. The correlation between ultrabright signals in FISH and the shortened 
overall survival time was not significant in our study. This can be attributed to the fact 
that the case number with ALT-positive FISH is too small. In conclusion, previous 
studies and our own study suggest that DAXX/ATRX loss and ALT phenotype is a late 
event in tumour progression, and is associated with larger tumours with malignant 
behaviour. In addition, according to Marinoni et al., chromosome instability (CIN) is 
induced in that kind of tumour, as part of tumour progression. 
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In siNETs, we revealed one case with a DAXX loss and no cases with a loss of 
expression of ATRX. The case with a DAXX loss was the primary tumour of a 50-year-
old woman with a tumour size of 0.8 cm. FISH revealed normal telomere signals. 
Further, we found one case with ALT phenotype; DAXX/ATRX expression was 
normal. The tissue of this case was a lymph node metastasis of a 6 cm primary tumour 
of a 67-year-old patient. The primary tumour also stained normal for DAXX/ATRX, 
and showed a normal signal in telomere FISH. This result is unique and contrasts with 
all our remaining cases and the studies undertaken to date. One explanation could 
therefore be that either DAXX or ATRX is mutated, but still positive in 
immunohistochemical staining. Another reason could be that another protein, which is 
altered, is involved in the regulation of telomeres. Histone H3.3 may be a candidate 
because decreased histone H3.3 leads to the destabilisation of telomeres [149]. 
Compared to our findings in insulinomas, the ALT phenotype seems to play a less 
important role in the pathogenesis. This is in line with the study by Dogeas et al., which 
revealed a 4% ALT pathway in liver metastasis of gastrointestinal NETs with carcinoid 
syndrome [187].  
In conclusion, we found that a loss of DAXX/ATRX expression correlated with ALT 
phenotype in insulinomas. Compared to studies with PANETs, there were fewer ALT-
positive cases in insulinomas since most insulinomas (90%) exhibit a benign behaviour. 
We revealed that a loss of DAXX/ATRX is correlated with malignant behaviour, a 
bigger tumour size and a shortened overall survival. In other words, finding a loss of 
expression of DAXX/ATRX in insulinomas is a sign of malignancy and a poor 
prognosis. In siNETs, loss of DAXX/ATRX expression and ALT phenotype play a 
minor role in the tumourgenesis. For insulinomas and other PANETs, mutations in the 
DAXX and ATRX gene represent a biological subtype, making it important to identify 
new targeted therapies. While inhibitors of the enzyme telomerase already exist, 
inhibitors of the ALT phenotype are lacking. For this reason, the mechanism of the ALT 
phenotype and the role played by DAXX and ATRX have to be investigated further.  
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6. Abstract 
 
Neuroendocrine tumours (NETs) are rare neoplasms with an incidence of 2- 4% per 
100,000 population. Most NETs are found in the pancreas (34.2%) and the small 
intestine (25.8%). At time of diagnosis, 50% of all patients with NETs already have 
metastasis and systemic therapy is indicated. There are drugs available like 
somatostatin- analogues, inhibitors of the mTOR pathway and inhibitors of 
angiogenesis and interferon alpha. For Somatostatin- analogues a stabilisation of tumour 
growth is reported. The other drugs showed a prolonged survival time for months 
compared to placebo. However, a better understanding of the biological mechanisms of 
this tumour type is necessary in order to find drugs for targeted therapy. Recent studies 
reported that mutations in the MEN1 gene, in the DAXX/ATRX gene and in genes related 
to the mTOR pathway are found in pancreatic neuroendocrine tumours (PANETs). Our 
aim is to examine the significance of DAXX/ATRX expression and alternative 
lengthening of telomeres (ALT) in insulinomas, which has been investigated in 
PANETs, but only for a small number of insulinomas. We also address this question in 
NETs of the small intestine (siNETs), which has not been examined at all. We found a 
loss of DAXX expression in one insulinoma and a loss of ATRX expression in four 
insulinomas. These results correlate with ALT phenotype (p< 0.001). We revealed that a 
loss of DAXX/ATRX is strongly correlated with malignant behaviour (p< 0.001), a 
bigger tumour size(p= 0.005) and a shortened overall survival (p=0.012). In other 
words, finding DAXX/ATRX expression loss in insulinomas is a sign of malignancy 
and a poor prognosis. In siNETs, loss of DAXX/ATRX expression and ALT phenotype 
play a minor role in the tumourgenesis. The ALT pathway plays an important role in 
insulinomas and PANETs in general, therefore further studies are required to find new 
agents for a targeted therapy. 
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7. Zusammenfassung 
 
Neuroendokrine Tumore sind seltene Tumoren mit einer Inzidenz von 2- 4% pro 100 
000 Einwohner. Pankreatische neuroendokrine Tumoren machen mit 34,2%  den 
größten Anteil und neuroendokrine Tumore des Dünndarms machen mit 25,8%  den 
zweitgrößten Anteil aller neuroendokriner Tumoren aus. Die Hälfte aller Patienten weist 
bereits zum Zeitpunkt der Diagnosestellung Metastasen auf und eine kurative operative 
Therapie ist nicht mehr möglich. Es gibt Medikamente wie Somatostatin-Analoga, 
Hemmstoffe des mTOR Pathways und der Angiogenese sowie Interferon alpha. 
Somatostainanaloga können das Tumorwachstum stabilisieren, die anderen 
Medikamente zeigen eine Verlängerung der Überlebensdauer für mehrere Monate. Neue 
Ansätze für eine zielgerichtete Therapie sind daher dringend notwendig. Neuere Studien 
zeigen dass Mutationen im MEN1 Gen, im DAXX/ATRX Gen und in den Genen des 
mTOR Signalwegs in pankreatischen neuroendokrinen Tumoren gehäuft auftreten. 
Diese Studie beschäftigt sich mit der immunhistochemischen DAXX/ATRX Expression 
in Insulinomen und in neuroendokrinen Tumoren des Dünndarms. Zu diesen Subtypen 
gibt es diesbezüglich bisher nur wenige Daten. Wir konnten zeigen dass auch in 
Insulinomen Verluste der DAXX/ATRX Expression  nach zu weisen sind und diese mit 
dem ALT Phänotyp (alternative Verlängerung der Telomere) in der FISH Untersuchung 
einhergehen. Ein Fall zeigte immunhistochemisch einen Ausfall für DAXX und vier 
Fälle zeigten einen Ausfall für ATRX. Diese Ergebnisse korrelierten mit dem ALT 
Phänotyp (p< 0,001). Des Weiteren konnten wir einen Zusammenhang zwischen 
DAXX/ATRX Ausflällen und malignem Verhalten (p< 0,001), erhöhter Tumorgröße 
(p= 0,005) und schlechterem Überleben zeigen (p= 0,012). Der immunhistochemische 
Nachweis von DAXX/ATRX Verlust spricht daher für ein Insulinom mit malignem 
Verhalten und einer schlechteren Prognose. In neuroendokrinen Tumoren des 
Dünndarms scheint dieser pathologische Mechanismus keine Rolle zu spielen. Für 
Insulinome und für pankreatische neuroendokrine Tumorn insgesamt spielt dieser 
Mechanismus eine wichtige Rolle in der Tumorgenese und bietet daher einen möglichen 
Ansatz für eine zielgerichtete Therapie. Hierfür sind noch weitere Untersuchungen zu 
diesem Mechanismus notwendig.   
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